Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer

Nikos F. Vlahos, Konstantinos P. Economopoulos, Stylianos Fotiou

Research output: Contribution to journalArticle

Abstract

There is evidence that endometriosis as well as drugs used in the process of in vitro fertilisation appear to associate with increased risk for gynaecological cancer. In this review, we attempt to describe this relationship according to the most recent epidemiologic data and to present the possible mechanisms on the molecular level that could potentially explain this correlation. There are data to support that ovarian endometriosis could have the potential for malignant transformation. Epidemiologic and genetic studies support this notion. It seems that endometriosis is associated with specific types of ovarian cancer (endometrioid and clear cell). There is no clear association between endometriosis and breast or endometrial cancer. More studies are needed to establish the risk factors that may lead to malignant transformation of this condition and to identify predisposed individuals who may require closer surveillance. Currently, there is no proven relationship between any type of gynaecological cancer and drugs used for infertility treatment. In principle, infertile women have increased risk for gynaecologic malignancies. Nulligravidas who received treatment are at increased risk for malignancy compared with women who had conceived after treatment. There is limited evidence that clomiphene citrate use for more than six cycles or 900 mg or treatment of women over the age of 40 could increase their risk for ovarian and breast cancer. More studies with the appropriate statistical power and follow-up time are required to evaluate accurately the long-term effects of these drugs and procedures.

Original languageEnglish (US)
Pages (from-to)39-50
Number of pages12
JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
Volume24
Issue number1
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Endometriosis
Fertilization in Vitro
Ovarian Neoplasms
Breast Neoplasms
Neoplasms
Fertility Agents
Clomiphene
Therapeutics
Endometrial Neoplasms
Pharmaceutical Preparations
Epidemiologic Studies

Keywords

  • breast cancer
  • cervical cancer
  • endometrial cancer
  • endometriosis
  • gynaecological cancer
  • in vitro fertilisation
  • ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. / Vlahos, Nikos F.; Economopoulos, Konstantinos P.; Fotiou, Stylianos.

In: Best Practice and Research: Clinical Obstetrics and Gynaecology, Vol. 24, No. 1, 02.2010, p. 39-50.

Research output: Contribution to journalArticle

@article{6235d12821ea411581b951c97fe49113,
title = "Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer",
abstract = "There is evidence that endometriosis as well as drugs used in the process of in vitro fertilisation appear to associate with increased risk for gynaecological cancer. In this review, we attempt to describe this relationship according to the most recent epidemiologic data and to present the possible mechanisms on the molecular level that could potentially explain this correlation. There are data to support that ovarian endometriosis could have the potential for malignant transformation. Epidemiologic and genetic studies support this notion. It seems that endometriosis is associated with specific types of ovarian cancer (endometrioid and clear cell). There is no clear association between endometriosis and breast or endometrial cancer. More studies are needed to establish the risk factors that may lead to malignant transformation of this condition and to identify predisposed individuals who may require closer surveillance. Currently, there is no proven relationship between any type of gynaecological cancer and drugs used for infertility treatment. In principle, infertile women have increased risk for gynaecologic malignancies. Nulligravidas who received treatment are at increased risk for malignancy compared with women who had conceived after treatment. There is limited evidence that clomiphene citrate use for more than six cycles or 900 mg or treatment of women over the age of 40 could increase their risk for ovarian and breast cancer. More studies with the appropriate statistical power and follow-up time are required to evaluate accurately the long-term effects of these drugs and procedures.",
keywords = "breast cancer, cervical cancer, endometrial cancer, endometriosis, gynaecological cancer, in vitro fertilisation, ovarian cancer",
author = "Vlahos, {Nikos F.} and Economopoulos, {Konstantinos P.} and Stylianos Fotiou",
year = "2010",
month = "2",
doi = "10.1016/j.bpobgyn.2009.08.004",
language = "English (US)",
volume = "24",
pages = "39--50",
journal = "Best Practice and Research in Clinical Obstetrics and Gynaecology",
issn = "1521-6934",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer

AU - Vlahos, Nikos F.

AU - Economopoulos, Konstantinos P.

AU - Fotiou, Stylianos

PY - 2010/2

Y1 - 2010/2

N2 - There is evidence that endometriosis as well as drugs used in the process of in vitro fertilisation appear to associate with increased risk for gynaecological cancer. In this review, we attempt to describe this relationship according to the most recent epidemiologic data and to present the possible mechanisms on the molecular level that could potentially explain this correlation. There are data to support that ovarian endometriosis could have the potential for malignant transformation. Epidemiologic and genetic studies support this notion. It seems that endometriosis is associated with specific types of ovarian cancer (endometrioid and clear cell). There is no clear association between endometriosis and breast or endometrial cancer. More studies are needed to establish the risk factors that may lead to malignant transformation of this condition and to identify predisposed individuals who may require closer surveillance. Currently, there is no proven relationship between any type of gynaecological cancer and drugs used for infertility treatment. In principle, infertile women have increased risk for gynaecologic malignancies. Nulligravidas who received treatment are at increased risk for malignancy compared with women who had conceived after treatment. There is limited evidence that clomiphene citrate use for more than six cycles or 900 mg or treatment of women over the age of 40 could increase their risk for ovarian and breast cancer. More studies with the appropriate statistical power and follow-up time are required to evaluate accurately the long-term effects of these drugs and procedures.

AB - There is evidence that endometriosis as well as drugs used in the process of in vitro fertilisation appear to associate with increased risk for gynaecological cancer. In this review, we attempt to describe this relationship according to the most recent epidemiologic data and to present the possible mechanisms on the molecular level that could potentially explain this correlation. There are data to support that ovarian endometriosis could have the potential for malignant transformation. Epidemiologic and genetic studies support this notion. It seems that endometriosis is associated with specific types of ovarian cancer (endometrioid and clear cell). There is no clear association between endometriosis and breast or endometrial cancer. More studies are needed to establish the risk factors that may lead to malignant transformation of this condition and to identify predisposed individuals who may require closer surveillance. Currently, there is no proven relationship between any type of gynaecological cancer and drugs used for infertility treatment. In principle, infertile women have increased risk for gynaecologic malignancies. Nulligravidas who received treatment are at increased risk for malignancy compared with women who had conceived after treatment. There is limited evidence that clomiphene citrate use for more than six cycles or 900 mg or treatment of women over the age of 40 could increase their risk for ovarian and breast cancer. More studies with the appropriate statistical power and follow-up time are required to evaluate accurately the long-term effects of these drugs and procedures.

KW - breast cancer

KW - cervical cancer

KW - endometrial cancer

KW - endometriosis

KW - gynaecological cancer

KW - in vitro fertilisation

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=76449118670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76449118670&partnerID=8YFLogxK

U2 - 10.1016/j.bpobgyn.2009.08.004

DO - 10.1016/j.bpobgyn.2009.08.004

M3 - Article

VL - 24

SP - 39

EP - 50

JO - Best Practice and Research in Clinical Obstetrics and Gynaecology

JF - Best Practice and Research in Clinical Obstetrics and Gynaecology

SN - 1521-6934

IS - 1

ER -